Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2418 | Low-Carbohydrate Diet Wiki | 0.58 |
| drug4964 | gym-based training Wiki | 0.58 |
| drug5256 | teleconsultation Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D006943 | Hyperglycemia NIH | 1.00 |
| D004700 | Endocrine System Diseases NIH | 0.33 |
| D018149 | Glucose Intolerance NIH | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000818 | Abnormality of the endocrine system HPO | 0.33 |
| HP:0000819 | Diabetes mellitus HPO | 0.09 |
Navigate: Correlations HPO
There are 3 clinical trials
The proposed randomized controlled trial will test the effect of a low-carbohydrate diet on hemoglobin A1c among individuals with elevated hemoglobin A1c that are within the range of prediabetes or diabetes. Results may provide evidence about the role of carbohydrate restriction in individuals with or at high risk of type 2 diabetes.
Description: Based on 10-year cardiovascular disease risk assessed by 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score
Measure: Change in estimated cardiovascular disease risk Time: Baseline and six monthsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a world health issue during the last months, affecting mostly countries with a high metabolic risk, like Mexico. Patients with type 2 diabetes (T2D) have an increased risk of any kind of infection as well as an increased mortality risk. Hyperglycemia has been established as an important predictor of mortality in patients with T2D and SARS-CoV-2. The standard treatment of hyperglycemia in hospitalized patients has been basen on insulin schemes, but recently evidence suggest the utility of some other drugs, reducing the risk of hypoglucemia and increasing the probability of a proper metabolic control. The goal of this study is to compare the utility of dipeptidyl peptidase-4 inhibitor (DPP4i) as a combination with insulin on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 and hyperglycemia.
Description: Glucose levels during hospitalization
Measure: Glucose levels Time: 5-10 daysDescription: Patients who achieve fasting glucose levels below 140 mg/dl and posprandial levels below 180 mg/dl
Measure: Number of patients who achieve metabolic control Time: 5-10 daysDescription: If the patient requires mechanical ventilation or dies
Measure: Number of patients who die or need mechanical ventilation Time: 5-10 daysDescription: C reactive protein measured at basal and at 5-10 days in mg/dl
Measure: C reactive protein levels Time: 5-10 daysThe physically inactive lifestyle of industrialised nations combined with the overconsumption of energy dense food has led to a global health emergency with >650 million adults classified as obese and ~400 million cases of type 2 diabetes worldwide. Physical inactivity is one of the leading global risks for mortality due to its association with cardio-metabolic pathologies such as cardiovascular disease and type 2 diabetes. Cognitive dysfunction is an important comorbidity of diabetes that affects well-being and diabetes management. Despite overwhelming evidence that an inactive lifestyle leads to chronic disease and premature death, many fail to meet activity guidelines. Therefore, novel strategies are urgently needed to combat the rising rates of metabolic disease and cognitive decline in our aging population. Inspired by current trends in the fitness market, Sphery Ltd. developed an immersive and motivating fitness exergame, the "ExerCube". The ExerCube allows a full-body workout that concurrently challenges physical and cognitive functions and adapts to the fitness and skill level of the individual. Previous research has shown that the ExerCube is an effective training method that is more enjoyable than conventional exercise training. Development of a home-based version of the ExerCube has the potential to make this system available to more individuals, and reduce major barriers to exercise, providing an attractive means to improve cardio-metabolic health of the population. Innovative home-based exergames are particularly in demand given the increase in the number of people wanting to exercise at home. Here, the investigators will combine the expertise of an interdisciplinary team of game researchers, game designers, exercise physiologists and metabolic researchers to further develop and evaluate a home-based version of the ExerCube that is designed to improve cardio-metabolic and cognitive health while effectively removing barriers to exercise in individuals at elevated risk of type 2 diabetes.
Description: Change in maximal aerobic capacity (VO2max)
Measure: VO2max Time: Following 6 weeks of trainingDescription: Change in maximal power output (Wmax)
Measure: Wmax Time: Following 6 weeks of trainingDescription: Training adherence indicated by number of training sessions performed over the 6-week period
Measure: Adherence Time: Following 6 weeks of trainingDescription: Number of participants that drop out from the study
Measure: Drop-out rate Time: 6 weeksDescription: Change in Physical Activity Enjoyment Scale (PACES) score (an 18-item scale designed to measure physical activity enjoyment)
Measure: Physical Activity Enjoyment Scale (PACES) score Time: Following 6 weeks of trainingDescription: Change in Situation Motivation Scale (SIMS) score
Measure: Situation Motivation Scale (SIMS) Time: Following 6 weeks of trainingDescription: Overall experience determined through qualitative interviews
Measure: Qualitative interviews Time: Following 6 weeks of trainingDescription: Change in Executive Functioning determined using Flanker test
Measure: Executive Functioning Time: Following 6 weeks of trainingDescription: Change in dynamic balance determined using Y-Balance Test
Measure: Dynamic balance Time: Following 6 weeks of trainingDescription: Change in whole body adipose tissue volume using InBody body composition analyser
Measure: Whole body adipose tissue Time: Following 6 weeks of trainingDescription: Change in visceral adipose tissue mass using InBody body composition analyser
Measure: Visceral adipose tissue Time: Following 6 weeks of trainingDescription: Change in fat free mass using InBody body composition analyser
Measure: Fat free mass Time: Following 6 weeks of trainingDescription: Change in blood pressure (systolic, diastolic and mean)
Measure: Blood pressure Time: Following 6 weeks of trainingDescription: Change in C-reactive protein
Measure: C-reactive protein Time: Following 6 weeks of trainingDescription: Change in total cholesterol
Measure: Total cholesterol Time: Following 6 weeks of trainingDescription: Change in triglycerides
Measure: Triglycerides Time: Following 6 weeks of trainingDescription: Change in HbA1c
Measure: HbA1c Time: Following 6 weeks of trainingDescription: Change in fasting glucose concentration
Measure: Fasting glucose concentration Time: Following 6 weeks of trainingDescription: Change in fasting insulin concentration
Measure: Fasting insulin concentration Time: Following 6 weeks of trainingDescription: Change in mean daily glucose concentration and area under the glucose curve
Measure: Mean daily glucose concentration and area under the glucose curve Time: Following 6 weeks of trainingDescription: Change in coefficient of variation in continuous glucose monitor
Measure: Coefficient of variation Time: Following 6 weeks of trainingAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports